Certara Introduces Certara.AI, the Life Sciences Specialized GPT Platform
Certara.AI Improves Drug Research & Development Processes with Secure, Client-Specific, A.I. Applications PRINCETON, N. J.—October…
Certara2023年10月5日
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
Hugo Geerts, Silke Bergeler, Mike Walker, Piet van der Graaf, Jean-Philippe Courade. Sci Rep. 2023…
Danielle Pillsbury2023年10月5日
How Modeling Can Help to Improve Children’s Access to Properly Evaluated Medications
Regulatory guidance paves the way to address ethical concerns in pediatric trials, and how additional…
Certara2023年10月5日
Clinical Pharmacology Issues That Can Lead to Approvability Problems for Your Drug
今日、臨床薬理情報は医薬品添付文書の50％以上を占めています。Inadequate clinical pharmacology development…
Danielle Pillsbury2023年10月4日
Certara Launches CoAuthor, a Regulatory and Medical Writing Tool
Using AI to gain efficiencies for medical writers PRINCETON, N. J.— 2023年10月3日— Certara,…
Certara2023年10月3日
Unlocking ROI through Omnichannel Stakeholder Engagement and Value Communication in Pharma
In a sector where both competition and stakeholder expectations are high, a comprehensive approach that…
Danielle Pillsbury2023年10月2日
Developing Pediatric PBPK Models for Differing Ethnic Populations
Physiologically-based pharmacokinetic (PBPK) modeling has proven invaluable in drug development, especially for pediatric populations, because…
Certara2023年9月29日
What recent paediatric guidelines mean for drug developers
Justin Hay, Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs…
Certara2023年9月25日
